Severe Neutropenia due to Carbimazole: Importance of Early Recognition & Management

Abstract

Background: Carbimazole, a frontline antithyroid medication, can rarely induce agranulocytosis or severe neutropenia—potentially 
life-threatening hematologic complications. Early detection and prompt intervention are essential to prevent serious outcomes. 

Case Presentation: A patient undergoing carbimazole therapy developed profound neutropenia. The diagnosis was established 
through comprehensive blood work detecting a significant drop in neutrophils. Immediate discontinuation of the drug, in addition 
to supportive measures such as granulocyte colony-stimulating factor (G-CSF) administration, led to rapid recovery of neutrophil 
counts. Regular monitoring allowed timely intervention before severe infection could ensue. 

Discussion: Although carbimazole-induced neutropenia is rare, clinicians must vigilantly monitor Complete Blood Counts (CBCs) 
during therapy. Patient education on early warning signs (fever, sore throat) is critical. This case supports existing literature on the 
reversibility of hematologic toxicity with appropriate management. 

Conclusion: High clinical suspicion, routine CBC monitoring, immediate drug cessation, and supportive therapies such as G-CSF 
are key in managing carbimazole-induced severe neutropenia. This case highlights the importance of early recognition to mitigate 
morbidity and offers a structured management algorithm for similar future events.